Monitor the Safety Monitoring Committee's review outcome and subsequent dose-escalation decision for SER-252. The pre-revenue status and small market cap imply high binary risk; a positive safety read could drive near-term upside, but historical returns on this ticker have been poor. Consider position sizing conservatively.
Price Chart
Executive Summary
Serina Therapeutics completed enrollment in Cohort 1 of its Phase 1b registrational trial for SER-252 (Parkinson's disease) ahead of prior guidance, a positive clinical milestone. However, Q1 2026 EPS of -$0.58 missed consensus estimates of -$0.35 by 65.7%, reflecting ongoing cash burn at a pre-revenue stage.
Key Financial Metrics
Key Facts
- All eight patients in Cohort 1 of the SER-252 Phase 1b trial have been enrolled and dosed ahead of the company's prior guidance (end of Q3 2026).
- Q1 2026 GAAP EPS -$0.58 vs consensus -$0.35 (-65.7% miss); revenue was $0 (pre-revenue).
- Safety Monitoring Committee will review Cohort 1 data to determine next dose-escalation step.
- Market cap ~$31M; pre-revenue clinical-stage biotech with no approved products.
Financial Impact
No revenue in Q1 2026; EPS miss of $0.23 per share vs consensus. Clinical catalyst is binary and not yet priced with certainty.
Risk Factors
- Clinical failure or safety signal in Cohort 1 could halt the program.
- Continued cash burn without revenue may require dilutive financing.
- Low trading liquidity and small float could amplify volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3331950 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $2.57 $2.16 | ▼ −15.95% | ▼ −14.86% | $1.51 (−41.24%) |
Jul 23, 2026 13w ago | Press Release | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.51 (−27.75%) |
Jul 22, 2026 13w ago | 8-K | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.51 (−27.75%) |
Jun 4, 2026 20w ago | EFFECT | $1.86 $1.81 | ▲ +2.69% | ▲ +0.14% | $1.51 (+18.81%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▼ −0.56% | ▼ −1.02% | $1.51 (−16.11%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▲ +0.56% | ▲ +1.02% | $1.51 (+16.11%) |
May 22, 2026 22w ago | S-3 | $1.92 $1.81 | ▲ +5.73% | ▲ +6.81% | $1.51 (+21.35%) |
Mar 27, 2026 30w ago | 10-K/A | $2.27 $2.15 | ▼ −5.29% | ▼ −9.15% | $1.51 (−33.48%) |
Mar 25, 2026 30w ago | Press Release | $2.61 $2.12 | ▼ −18.77% | ▼ −20.41% | $1.51 (−42.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers